Genohope Participates in The 15th Dhaka Pharma Exhibition in Bangladesh

On February 28th, Chairman Tang Xun and CEO Zhang Haoteng of Genohope, along with the international BD team, participated in the three-day 15th Dhaka Pharma Exhibition, Asia Pharma Expo.

Overview of the Exhibition

The Bangladesh Pharmaceutical Exhibition, known as the largest pharmaceutical industry exhibition in Bangladesh, attracts pharmaceutical companies, industry experts, scholars, and media representatives from around the world. It aims to promote international exchange and cooperation in the pharmaceutical field, and to drive the healthy development of the pharmaceutical industry in Bangladesh and globally.

Highlights of the Exhibition

High level of internationalization: The Bangladesh Pharmaceutical Exhibition attracts pharmaceutical companies from various countries and regions around the world, providing a broad platform for international exchange and cooperation.

Prominent technological innovation: The exhibition showcases numerous cutting-edge pharmaceutical technologies and innovative drugs, injecting new vitality into the industry's development.

Strong professionalism: The exhibition brings together many experts and scholars in the pharmaceutical field, providing industry professionals with opportunities for in-depth communication and learning."

Participation Value:

Participating in the Bangladesh Pharmaceutical Exhibition holds immense value for Genohope. Firstly, this exhibition serves as a crucial gateway for Genohope to enter the Bangladeshi market. Through the exhibition, we gain further insights into international market demands and trends, aiding Genohope in seizing market opportunities. Secondly, this exhibition provides Genohope with a platform to engage in in-depth communication with global counterparts and expand cooperation networks. Lastly, this exhibition serves as a significant stage for Genohope to showcase its corporate strength and enhance brand image.

Stepping beyond borders and envisioning the future, Genohope actively participates in driving the prosperity and development of the global pharmaceutical industry.

Fujian Genohope Biotechnology Co., Ltd. was established in January 2019. It is a joint venture between Taiwan's Lin Yang Biotechnology Company and the New Hope Group Medical Fund, a Fortune Global 500 company. Genohope is the first demonstration project in the "Cross-Strait Biotechnology and Medical Health Industry Cooperation Zone" and the first CDMO pharmaceutical company in Fujian Province to integrate the research, development, production, and sales of active pharmaceutical ingredients and injectables. Its products include fully synthetic and semi-synthetic semi-fermented peptide drugs, small molecule anticancer drugs, and monoclonal antibody drugs.